Luca Mologni

18PUBLICATIONS
82CO-AUTHORS
Molecular targetsCancer diagnosisHaematological tumoursSolid tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jun 19, 2026
Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models.

|Oct 29, 2025
A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma.

Nagarajan Pattabiraman, Cosimo Lobello, David Rushmore

|Mar 13, 2025
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis.

Federica Malighetti, Matteo Villa, Alberto Maria Villa

|Jan 08, 2025
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.

Federica Malighetti, Matteo Villa, Mario Mauri

|Oct 31, 2024
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.

Matteo Villa, Geeta G Sharma, Federica Malighetti

|May 15, 2024
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.

Diletta Fontana, Federica Malighetti, Matteo Villa

Pageof 3

Frequent Collaborators

7 joint publications

Federica Malighetti

7 joint publications

Rocco Piazza

7 joint publications

Matteo Villa

6 joint publications

Daniele Ramazzotti